17 completed, 13 active not recruiting, 12 terminated, 9 recruiting. 56 Phase 2, 11 Phase 1, 1 Phase 3.
Follow encorafenib: new trials by email Literature Review of encorafenib trials Research Report on encorafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations Rechalange with bevacizumab + encorafenib - Colo-rectal Cancer | Phase 2 | Not yet recruiting | Vall d'Hebron Institute of Oncology | 25 | 2025-10-01 | 2025-09-17 |
| Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases Encorafenib + Binimetinib, cemiplimab+fianlimab - Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases | Phase 2 | Recruiting | Grupo Español Multidisciplinar de Melanoma | 33 | 2025-05-29 | 2025-10-01 |
| Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC Cetuximab, Encorafenib - Colorectal Cancer | Phase 2 | Completed | Gruppo Oncologico del Nord-Ovest | 16 | 2024-07-23 | 2026-10-28 |
| Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. encorafenib + cetuximab + FOLFIRI - Colorectal Carcinoma, Colorectal Neoplasms | Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 25 | 2024-06-03 | 2025-02-12 |
| Combination Therapy for BRAF-V600E Metastatic CRCm Encorafenib, Cetuximab, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Vall d'Hebron Institute of Oncology | 94 | 2024-05-17 | 2024-11-08 |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma Defactinib, Avutometinib, Encorafenib - Cutaneous Melanoma, Brain Metastases | Phase 1 / Phase 2 | Recruiting | University of Utah | 33 | 2024-03-20 | 2025-12-03 |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Pembrolizumab, Encorafenib, Binimetinib - Malignant Melanoma, Metastatic Melanoma | Phase 2 | Completed | Dr. Ronnie Shapira | 1 | 2023-09-05 | 2025-07-22 |
| Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Encorafenib, Cetuximab, Biospecimen Collection - Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma | Phase 2 / Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1 | 2023-08-16 | 2026-07-02 |
| A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma encorafenib, binimetinib, pembrolizumab - Melanoma | Phase 2 | Terminated | Pfizer | 38 | 2023-06-13 | 2026-03-09 |
| Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma Encorafenib + Binimetinib, Standard Adjuvant Treatment - Melanoma, Cancer | Phase 2 | Active not recruiting | CCTU- Cancer Theme | 18 | 2023-02-27 | 2026-10-26 |
| Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer Encorafenib Oral Capsule + Cetuximab - Colorectal Cancer, BRAF V600E Mutation Positive | Phase 2 | Recruiting | Federation Francophone de Cancerologie Digestive | 30 | 2023-02-13 | 2025-09-02 |
| Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab - Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer | Phase 2 | Terminated | Northwestern University | 7 | 2022-10-10 | 2026-06-12 |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Alectinib, Cetuximab, Crizotinib - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2022-09-27 | 2023-02-21 |
| Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis Stereotaxic radiosurgery (SRS), Binimetinib Oral Tablet, Encorafenib Oral Capsule - Malignant Melanoma, BRAF V600 Mutation | Phase 2 | Active not recruiting | UNICANCER | 10 | 2022-09-05 | 2026-06-05 |
| Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer Binimetinib - Colorectal Cancer, Colon Cancer | Phase 2 | Completed | AIO-Studien-gGmbH | 2 | 2022-09-01 | 2025-10-01 |
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation Cetuximab, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-07-19 | 2026-07-08 |
| A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer Encorafenib, Cetuximab, Pembrolizumab - Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | Pfizer | 108 | 2022-07-11 | 2026-07-31 |
| Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Encorafenib, Binimetinib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Pierre Fabre Medicament | 63 | 2022-06-02 | 2026-05-01 |
| StrataPATH™ (Precision Indications for Approved Therapies) lorlatinib, encorafenib + binimetinib, talazoparib - Cancer, Advanced Solid Tumor | Phase 2 | Terminated | Strata Oncology | 11 | 2022-04-29 | 2025-01-08 |
| (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma Encorafenib + Binimetinib - Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma | Phase 2 | Unknown | Leiden University Medical Center | 28 | 2022-01-01 | 2023-03-14 |
Showing 20 of 56. Sign in to see all of them.
Melanoma (24) · Colorectal Neoplasms (14) · Brain Neoplasms (8) · Colonic Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (4) · Neoplasms (4) · Lung Neoplasms (3) · Rectal Neoplasms (3) · Pancreatic Neoplasms (2) · Astrocytoma (1) · Digestive System Neoplasms (1) · Disease Progression (1) · Gastrointestinal Neoplasms (1) · Glioblastoma (1)
Pfizer (9) · Array BioPharma (3) · M.D. Anderson Cancer Center (3) · Pierre Fabre Medicament (3) · Grupo Español Multidisciplinar de Melanoma (2) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (2) · Vall d'Hebron Institute of Oncology (2) · AIO-Studien-gGmbH (1) · Academic and Community Cancer Research United (1) · Alliance for Clinical Trials in Oncology (1) · Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · CCTU- Cancer Theme (1) · Dr. Ronnie Shapira (1) · ECOG-ACRIN Cancer Research Group (1)
United States (32) · Spain (15) · Italy (13) · Australia (10) · France (10) · Germany (10) · Netherlands (9) · Canada (8) · Belgium (7) · United Kingdom (6) · Poland (4) · Switzerland (4) · Denmark (3) · Norway (3) · Austria (2)
Array BioPharma (2) · Van K Morris (2) · Alexander Stein, Prof. Dr. (1) · Alfonso Berrocal Jaime, M.D. (1) · Andrew E Hendifar (1) · Anna Spreafico, MD (1) · Antoni Ribas (1) · Carlotta Antoniotti, MD, PhD (1) · Caroline Robert (1) · Charles Ricordel (1) · Claire Gallois, MD (1) · David Planchard (1) · Devalingam Mahalingam, MD, PhD (1)
PMID 35385748, PMID 19942357, PMID 26112811, PMID 27288470, PMID 28592387, PMID 32669376, PMID 34376578, PMID 34625515, PMID 34655839, PMID 34774225, PMID 34918546, PMID 34986285, PMID 36049147, PMID 36608320, PMID 36763936, PMID 36811382, PMID 37270692, PMID 37815847, PMID 38167503, PMID 38698170, PMID 38900987, PMID 38946469, PMID 39315864, PMID 40439484, PMID 40449497, PMID 40480428, PMID 40578933, PMID 41109959, PMID 41852303, PMID 41910021, PMID 41914670, PMID 41915880, PMID 42550831, PMID 42612509
2023 (3), 2014 (2), 2018 (2), U10CA180888 (2), 2017 (1), 2019 (1), P01CA168585 (1), P30CA015083 (1), P30CA060553 (1), U10CA180820 (1), UM1CA137443 (1)